<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_CGU_Taiwan_Proof skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:CGU Taiwan/Proof</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><HEADER class="top"><UL class="header-subnav"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan">HOME</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Achievements">ACHIEVEMENTS</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Description">PROJECT</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Software">MODELING</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices">HUMAN PRACTICES</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Team">PEOPLE</A></LI><LI class="dropdown"><A href="https://2016.igem.org/Team:CGU_Taiwan/Interlab">INTERLAB</A></LI><LI class="dropdown"><A href="https://2016.igem.org/Team:CGU_Taiwan/Safety">SAFETY</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Parts">PARTS</A></LI></UL></HEADER><DIV class="left"><A href="#anchor1"><SECTION class="left-tab" style="top:240px;" id="myP" onmousedown="mouseDown()" onmouseup="mouseUp()"><B>TOP</B></SECTION></A><A href="https://2016.igem.org/Team:CGU_Taiwan/Description"><SECTION class="left-tab" style="top:275px;left:50px;">Overview</SECTION></A><A href="https://2016.igem.org/Team:CGU_Taiwan/Design"><SECTION class="left-tab" style="top:310px;left:50px;">Design</SECTION></A><A href="https://2016.igem.org/Team:CGU_Taiwan/Background"><SECTION class="left-tab" style="top:345px;left:50px;">Background</SECTION></A><A href="https://2016.igem.org/Team:CGU_Taiwan/Results"><SECTION class="left-tab" style="top:380px;left:50px;">Results</SECTION></A><A href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><SECTION class="left-tab" style="top:415px;left:50px;">Proof</SECTION></A><A href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><SECTION class="left-tab" style="top:450px;left:50px;">Notebook</SECTION></A></DIV><DIV class="mid" style="top:180px;margin-left:15%;margin-top:6%;"><DIV style="font-size:60px;color:#66B3FF;text-decoration:none;">
Proof of Concept
</DIV><B><FONT size="5px">1. We established stable Leishmania transfectants and proved the function of
promotor with hygromycin drug selection gene</FONT></B><DIV style="color:black;text-decoration:none;font-size:18px;margin-left:70px;margin-right:15%;">
The promoter and the ribosomal binding site of Leishmania genome has not
been elucidated yet. We selected the 5'- untranslated region of a highly expressed
gene, P36, to be the promoter, RBS binding site and other extra function needed for
Leishmania protein expression. We also added a hygromycin resist gene to serve as a
dual functional biobrick of regulatory and selection marker. We provide the user with
the regulation of protein expression and also the drug selection system that is most
commonly and effectively used in Leishmania experiments.
The pSB1C3-5'HYG-OVA-3'UTR was transfected into Leishmania 12-DT strain,
and the transfectants were selected by hygromycin. We obtained the
hygromycin-resistant Leishmania transfectants (Figure 1. B, C). In the negative control
group (Figure 1. A), we could see that almost all cells were dead and the shape of
Leishmania was not normal. It showed that Leishmania transfectants were resistant
to high concentration of hygromycin. The function of 5â€™HYG was assayed more
precisely in figure 2.
</DIV><B><FONT size="6px">2. Successfully expressed Hemagglutinin of H1N1</FONT></B><DIV style="color:black;text-decoration:none;font-size:18px;margin-left:70px;margin-right:15%;">
Since we are performing immunology experiments, it is very important that the
antigen is correctly expressed. We used BL21 competent cell to express the HA
sequence and detect the protein by Western blot analysis.
The pSB1C3-J04500-HA can is checked by Western blot analysis. We successfully
recognize the HA protein from Western blot analysis (approximately 62.3kd) when
induced by IPTG (Figure 3.).</DIV><B><FONT size="6px">3. The antibody production of Leijuvant in mice</FONT></B><DIV style="color:black;text-decoration:none;font-size:18px;margin-left:70px;margin-right:15%;">
The IgG1 antibody titer increased drastically after the second boost on the 15<SUP>th</SUP> day.
And the antibody titer reached to peak on the 25<SUP>th</SUP> day <B>(Figure 4A.)</B>. Inactivated
Leishmania can achieve over 60% of the antibody titer. As for OVA-expressing
inactivated Leishmania, the antibody titer can reach to 70% on the 25<SUP>th</SUP> day. The
IgG2a antibody titer of inactivated Leishmania increased extremely on the 20<SUP>th</SUP> day
and is significantly higher compare to Alum on the 25<SUP>th</SUP> day<B>(Figure 4B.)</B>. <B>Leijuvant</B> is a
potential <B>bi-pathway</B> adjuvant that can stimulate both Th1 and Th2 immune 
responses.</DIV></DIV><DIV class="end2" style="margin-top:220%;"><UL class="list3" class="margin-left:1%;margin-top:2%;"><LI><A href="#anchor1"><B style="color:white;font-size:28px;margin-left:7%;">TOP</B></A></LI></UL><DIV class="sitemap" style="margin-left:5%;"><B style="color:white;font-size:28px;margin-top:5%;margin-left:4%;text-decoration:none;">SITE MAP</B></DIV><DIV class="sitemap" style="margin-left:22%;margin-top:-1%;"><UL class="list1" class="margin-left:5%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan"><B style="color:white;font-size:18px;margin-left:20%;">HOME</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><B style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><B style="color:white;font-size:18px;margin-left:20%;">INTERLAB</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><B style="color:white;font-size:18px;margin-left:20%;">SAFETY</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><B style="color:white;font-size:18px;margin-left:20%;">PARTS</B></A></LI></UL></DIV><DIV class="sitemap" style="margin-left:40%;margin-top:-2%;"><UL class="list1" class="margin-left:5%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Description"><B style="color:white;font-size:18px;margin-left:20%;">PROJECT</B></A></LI><UL class="list2" class="margin-left:6%;margin-top:50%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Design"><B style="color:white;font-size:17px;margin-left:10%;">Design</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Background"><B style="color:white;font-size:17px;margin-left:10%;">Background</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Results"><B style="color:white;font-size:17px;margin-left:10%;">Results</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><B style="color:white;font-size:17px;margin-left:10%;">Proof</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><B style="color:white;font-size:17px;margin-left:10%;">Notebook</B></A></LI></UL></UL></DIV><DIV class="sitemap" style="margin-left:55%;margin-top:-3.5%;"><UL class="list1" class="margin-left:5%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><B style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</B></A></LI><UL class="list2" class="margin-left:6%;margin-top:50%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><B style="color:white;font-size:17px;margin-left:10%;">Survey</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><B style="color:white;font-size:17px;margin-left:10%;">Education</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><B style="color:white;font-size:17px;margin-left:10%;">Communication</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><B style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</B></A></LI></UL></UL></DIV><DIV class="sitemap" style="margin-left:75%;margin-top:-3.5%;"><UL class="list1" class="margin-left:5%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Software"><B style="color:white;font-size:18px;margin-left:20%;">MODELING</B></A></LI><UL class="list2" class="margin-left:6%;"><LI><A href="http://163.25.92.36/igemcgu/igemwebhome.htm"><B style="color:white;font-size:17px;margin-left:10%;">McHug</B></A></LI></UL></UL><UL class="list1" class="margin-left:1%;margin-top:-10%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Team"><B style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</B></A></LI><UL class="list2" class="margin-left:6%;margin-top:-5%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><B style="color:white;font-size:17px;margin-left:10%;">Collaborations</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><B style="color:white;font-size:17px;margin-left:10%;">Attributions</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Team#anchor2"><B style="color:white;font-size:17px;margin-left:10%;">Sponsors</B></A></LI></UL></UL></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>